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Objectives: To determine the publicly funded health care costs associated 
with breast cancer (BC) by stage of disease in the first two years following diag-
nosis. MethOds: Incident cases of female invasive BC (ICD-9 174.x) diagnosed 
between 2005 and 2009 were extracted from the provincial cancer registry and linked 
by their encrypted health card number to administrative datasets. The type and 
usage of publicly funded health care services used were stratified by disease stage 
over the first two years following diagnosis. BC cases were matched to controls 
(women without cancer). Overall average costs (2008$CAN) and costs per resource 
per BC case were compared to a control group. The attributable cost for the two-year 
time horizon was determined. Results: There were 39,655 BC cases and 190,520 
controls in our cohort study. The average age was 61.1 years old and 60.9 years old, 
respectively. Of the BC cases with staging information, the majority of cases were 
Stage I (34.4%) and Stage II (31.8%). Eight percent of the entire cohort died within 
the first two years of diagnosis. The overall mean cost per BC case from a public 
payer perspective in the first two years following diagnosis was $41,686 based on the 
study cohort of 39,655 BC cases. The mean cost increased by stage: Stage I ($29,938), 
Stage II ($46,893), Stage III ($65,369) and IV ($66,627). When compared to controls, 
the net cost for BC cases was $31,732. Cost drivers for the entire cohort were can-
cer clinic visits, physician billing and inpatient hospitalizations. cOnclusiOns: 
Costs increased by stage of disease. Cost drivers were identified and a net cost was 
calculcated. This data will allow for planning and decision making around limited 
health care resources.
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Objectives: Mixed results have been reported on the associations between insur-
ance coverage and cancer treatment, probably due to different population involved. 
This study was conducted to investigate treatment patterns by insurance status 
in patients with breast cancer using a large national database. MethOds: The 
National Cancer Database (NCDB) was used to examine the initial treatment after 
diagnosis. Patients were classified into the early stage group (stage 0-2) and the 
advanced stage group (stage 3-4). Logistic regressions were used to estimate the 
Odds ratios (ORs, with confidence intervals [95% CIs]) of receiving surgery, hor-
mone therapy, and chemotherapy by insurance status. Results: A total of 2,317,286 
patients with breast cancer were retrieved from the database during the study 
period (2000-2011). Patients with private insurance, Medicare, Medicaid or no insur-
ance accounted for 53.8%, 35.5%, 4.8%, and 2.2% respectively. Compared with the 
uninsured, patients with private insurance, Medicare, or Medicaid were more likely 
to receive surgery in both early stage group (OR 2.97, [2.83-3.11], OR 2.00, [1.90-2.09], 
OR 1.58, [1.49-1.67] respectively) and advanced stage group (OR 2.89, [2.78-3.01], OR 
1.45, [1.39-1.51], OR 1.60, [1.53-1.68] respectively). In the early stage group, patients 
with private insurance and Medicare were more likely to undergo partial mastec-
tomy than the uninsured (OR 1.40, [1.37-1.43], OR 1.36, [1.33-1.39]), while patients 
with Medicaid had similar utilization of partial mastectomy as the uninsured 
(OR 1.02, [1.0-1.05]). In the advanced stage group, patients with private insurance, 
Medicare, or Medicaid were more likely to receive hormone therapy (OR 1.54, [1.48-
1.60], OR 1.68, [1.61-1.74], OR 1.20, [1.15-1.26]) than the uninsured. Patients with 
private insurance and Medicaid were also more likely to receive chemotherapy (OR 
1.67, [1.60-1.74], OR 1.39, [1.32-1.46]), while patients with Medicare were less likely 
to receive chemotherapy (OR 0.36, [0.34- 0.37]) than the uninsured. cOnclusiOns: 
Insurance status is associated with different treatment patterns. It may have an 
impact on clinical management of patients with breast cancer.
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Objectives: The study aims to systematically review the efficacy, safety and 
cost-effectiveness of trastuzumab in metastatic gastric cancer treatment in 
China. MethOds: A systematic review method was performed. We collected both 
national and international clinical, cost-effectiveness and disease burden stud-
ies mainly from database of Pubmed, MEDLINE, CNKI, etc. And health insurance 
status of trastuzumab in China was also collected. Results: With inclusion and 
exclusion criteria, there were 8 clinical studies, 2 cost-effectiveness study and 19 
disease burden studies finally recruited for the analysis. Clinical results showed 
that trastuzumab in combination with chemotherapy were effective and well toler-
ated in target population. In ToGA, the only phase III randomized controlled trial, 
compared with chemotherapy alone, trastuzumab plus chemotherapy substantially 
improved overall survival (13.8 vs. 11.1 months) and progression-free survival (6.7 
vs. 5.5 months). One cost effectiveness study revealed that from the perspective of 
UK NHS, ICER of trastuzumab plus chemotherapy among IHC3+ or IHC2+/FISH+ 
patients was 66,982-71,637 pounds per QALY, compared with chemotherapy alone. 
Gastric cancer had brought a heavy disease burden to China. The DALY lost from 
gastric cancer was 1.48-5.03 per thousand patients and average hospitalization 
expenditure per patient was rising. By the first half year of 2013, there were more 
than 6 provinces and cities in China providing public reimbursement for trastu-
zumab, but only 2 for gastric cancer indication. cOnclusiOns: Trastuzumab with 
chemotherapy can be considered as a new standard option for HER2-positive meta-
static gastric cancer patients. However, more evidences on efficacy, safety and cost 
effectiveness of trastuzumab are still needed to support local public decision making 
on health insurance benefits update in China.
the DDD results indicated small declines in medication adherence for cancer sur-
vivors relative to beneficiaries without a cancer diagnosis in all three drug classes 
(3 to 5 percentage points), whereas longer term cancer survivors had much better 
adherence to all three drug classes (10 to 12 percentage points higher) relative to 
beneficiaries with cancer who had a poor prognosis. cOnclusiOns: A diagnosis of 
cancer among Medicare beneficiaries with diabetes significantly reduces adherence 
with evidence-based medications recommended in diabetes treatment guidelines.
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Objectives: To examine total health care-expenditures in the initial phase-of-care 
among Medicare beneficiaries with colorectal cancer (CRC) from a rural setting, 
and compare them with “national” estimates. MethOds: A population-based ret-
rospective cohort-study was conducted on fee-for-service Medicare beneficiaries 
aged ≥ 66 years diagnosed with CRC between 2003-2006 identified from the West 
Virginia Cancer Registry (WVCR)-Medicare linked database (n= 2,114). Similarly, a 
comparative cohort was identified from Surveillance, Epidemiology, and End Results 
(SEER)-Medicare (n= 38,172). Medicare claim payment-amounts were used to cal-
culate total average health care, inpatient, outpatient, physician-visits, and other 
health care-utilization expenditures. To control for geographic variation in cost-of-
living across the different counties, health care-expenditures were expressed using 
county-specific cost-of-living indices (COLI). Results: After COLI-adjustment, the 
average total health care expenditures in the initial phase-of-CRC care for those 
from the WVCR-Medicare linked-database were estimated at $46,644. The average 
total health care and inpatient expenditures in initial phase-of-care were found to 
be lower (5% and 4%, respectively) for those from WVCR-Medicare as compared to 
those from SEER-Medicare. However, they had a higher co-morbidity burden, and 
significantly higher (45%) outpatient expenditures as compared to their “national” 
counterparts. The outpatient expenditures were higher specifically for beneficiaries 
with chronic-conditions, which have a higher prevalence in the WVCR-Medicare 
group as compared to those from SEER-Medicare. Further, the differences in total 
health care-expenditures between beneficiaries from WVCR-Medicare and SEER-
Medicare reduced from $2,282 to $898, and remained no longer significant in a 
multivariable setting after controlling for receipt of minimally-appropriate CRC 
treatment (MACT) and presence of chronic-conditions. cOnclusiOns: This study 
highlights the importance of providing preventive health care services and better 
co-management of CRC and chronic-conditions, to control the higher outpatient 
expenditures among beneficiaries with CRC from a rural population. This study 
also showed that the differences in total health care-expenditures between rural 
and “national” population are likely to be partially explained by the receipt of MACT 
and comorbidity-burden.
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Objectives: To examine colorectal cancer (CRC) treatment patterns in the ini-
tial phase-of-care, the extent of receipt of minimally-appropriate CRC-treatment 
(MACT), the associated survival in a three-year period following a CRC-diagnosis 
in Medicare beneficiaries diagnosed with CRC from a rural setting, and to com-
pare these findings with “national” estimates. MethOds: A population-based 
retrospective cohort-study was conducted with data from fee-for-service Medicare 
beneficiaries aged ≥ 66 years diagnosed with CRC between 2003-2006 identified from 
the West Virginia Cancer Registry (WVCR)-Medicare linked database (n= 2,119). A 
comparative “national” cohort was identified from Surveillance, Epidemiology, and 
End Results (SEER)-Medicare (n= 38,168). CRC-treatment received was ascertained 
from beneficiaries’ Medicare claims by following them for 12-months from their 
CRC-diagnosis date or until death. Receipt of MACT was defined based on National 
Cancer Institute CRC-treatment guidelines. All-cause and CRC-specific mortality 
in the 36-month period following CRC-diagnosis were examined after accounting 
for selection bias using inverse probability treatment weights. Results: Although 
a higher proportion of beneficiaries from WVCR-Medicare were diagnosed in the 
earlier stages of CRC (when it can still be treated effectively) as compared to their 
SEER-Medicare counterparts, they had poorer CRC-survivorship with adjusted haz-
ards ratio (AHR)= 1.26;95%CI= [1.20,1.32]. This poorer survivorship may be due to 
a lower-likelihood (adjusted odds ratios (AOR)= 0.85;95%CI= [0.76,0.96]) of benefi-
ciaries from WVCR-Medicare of receiving MACT as compared to their “national” 
counterparts. Differences in usage of CRC-surgery, chemotherapy and radiation 
were also observed in the two populations. Those from WVCR-Medicare were less 
likely to receive any type of CRC-surgery with AOR= 0.82;95%CI= [0.73,0.93]. cOnc
lusiOns: This study highlights the need for an increased emphasis on adoption 
and adherence to accepted surgical and adjuvant CRC-treatment guidelines, and 
improving access to CRC-care for those from rural-settings. Further research needs 
to be conducted to determine if similar rural-urban differences in receipt of MACT 
exist in the elderly in other rural-areas of the nation.
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drugs for severe diseases to become available earlier in their development cycle but 
risks approving ineffective and/or unsafe drugs.
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Objectives: To study patient’s out-of-pocket expenditures in patients taking oral 
oncology medication for the treatment of Multiple Myeloma who are enrolled in 
a specialty pharmacy program. MethOds: A retrospective analysis of pharmacy 
claims and reimbursement data for oncology patients enrolled in a specialty phar-
macy program and receiving biologic drugs from January 1, 2013 through October 
31, 2013 was conducted. Patients with a primary diagnosis of Multiple Myeloma 
(ICD-9 CM: 203.xx) prescription data were included. There were no exclusion criteria. 
The distribution of out-of-pocket patient’s costs per prescription were performed 
comparing average co-pay responsibility per prescription after insurance to aver-
age patient co-pay per prescription after funding assistance. Results: A total 
of 22,566 prescriptions were included. The average patient co-pay responsibility 
after insurance was $435.00 per prescription and the average patient co-pay after 
funding assistance was $81.00 per prescription. This resulted in 12,822 (91.17%) of 
the prescriptions had a patient co-pay of under $10.00 after funding assistance. 
The patient’s insurance type was as follows: private insurance was 59%, Medicare 
was 25%, Pharmacy Benefit Manager was 10%, Tricare was 1%, and Medicaid was 
5%. cOnclusiOns: In this retrospective analysis of pharmacy and financial claims 
data, Multiple Myeloma patients significantly reduced their out-of-pocket expen-
ditures, from an average of $435.00 to $81.00 by the specialty pharmacy gaining 
funding assistance for the patient.
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Objectives: To assess imaging and treatment patterns in head and neck cancer 
(HNC) patients using a large commercial-insurance database from the United States 
(U.S.). MethOds: We used the Marketscan® Research Databases (2007-2011) to 
identify adults with HNC (oral, pharynx, paranasal sinus, larynx) using ICD-9 codes. 
We evaluated three periods of imaging and treatment patterns: 1) three months 
pre-diagnosis, 2) diagnosis-to-treatment initiation, and 3) post-treatment initia-
tion. Patients receiving single-imaging modalities and multiple-imaging modali-
ties were evaluated in relation to surgery, chemotherapy, radiation therapy, and 
combinations. Imaging and treatment intensity and variability by cancer types and 
geographic regions (Northeast, North Central, South, and West) were assessed using 
multinomial and multivariate logistic regression. Results: 80,987 patients were 
analyzed (39% female, mean age: 60 years). During pre-treatment, comparing all 
cancer types to oral cancer, pharynx cancer patients had the greatest likelihood 
of single-modality imaging and multiple-modality imaging. Patients with higher 
comorbidity index scores were more likely to receive more intensive imaging prior 
to treatment. Pre-treatment imaging was more likely to occur in other regions com-
pared to West (OR range: 1.07-1.29), with consistent imaging patterns versus the 
West following treatment. There was limited regional variability in single and/or 
multiple intervention patterns. In the post-treatment period, patients receiving 
multiple treatment interventions, a proxy for advanced cancer, were more likely to 
undergo PET/CT. A high portion of larynx cancer patients received surgery (37%). 
Pharynx cancer patients were more likely to receive radiation therapy (24%) and/or 
chemotherapy (30%). During all phases combined, females were less likely to get 
imaging of any type (x-ray, CT, or PET/CT) (OR range: 0.71-0.91). cOnclusiOns: 
Commercially-insured HNC patients in the U.S. vary in imaging intensity and in the 
types of imaging modalities used, prior to and following initial diagnoses. Receiving 
multiple treatment interventions was associated with undergoing multiple imaging 
tests and more specifically, PET/CT.
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Objectives: To describes treatment patterns among patients initiating regorafenib, 
an oral kinase inhibitor indicated for the treatment of metastatic colorectal cancer 
in patients who have tried other first-line therapies. MethOds: Pharmacy and 
medical claims from Humana, a large national U.S. payer, were used. The study 
sample included patients age 19 to 89 years with at least one claim for regorafenib 
between 9-27-2012 and 6-1-2013. A subset of patients with pharmacy and medical 
benefits, as well as pre-index continuous enrollment of at least 12 months, was 
used to examine prior exposure to chemotherapy, radiation, and biologic thera-
pies. Patients were followed until death, disenrollment or study end date (10-31-
2013). Results: A total of 407 patients with claims for regorafenib were identified. 
The mean age was 66.4 years, 53.1% were male, and median length of follow up was 
140 days (range of 0-357 days). Median length of pre-index continuous enrollment 
was 779 days. The majority resided in the southern (51.6%) and midwestern (26.0%) 
U.S. and most patients had Medicare Advantage (26.0%) or Medicare Part D (69.3%) 
coverage. A total of 91 regorafenib patients met all inclusion/exclusion criteria. 
Metastatic cancer diagnosis was observed in 93.4% of patients; the majority had 
liver metastases. Common pre-index comorbidities included hypertension (72.5%), 
fluid/electrolyte disorders (41.8%), chronic pulmonary diseases (25.3%), diabetes 
(34.1%), and depression (15.4%). Evidence of chemotherapy, biologic therapy, and 
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Objectives: Drug shortages are a global problem. While extensively studied in the 
United States, numbers about drug shortages in European countries are scarce. This 
study aims to investigate publically available data about drug shortages in European 
countries in order to reveal a typology of drug shortages in Europe. MethOds: A 
standardized reporting template was designed based on a literature search to collect 
and structure information. Countries offering an online reporting system for drug 
shortages such as Belgium, The Netherlands, England, Italy, France, Germany and 
Spain are included in this study. The online reporting systems were consulted in 
May 2013. Typology and causes of drug shortages are mapped and a sub-analysis is 
performed for essential medicines and oncology drugs. Results: Majority of drugs 
reported to suffer from shortage (n= 671) are branded (61%), oral drugs (51%) that 
equally affect different disease domains. When considering essential medicines 
(n= 200) and oncology drugs (n= 71), generics (55% for essential drugs, 64% for oncol-
ogy drugs) and injectables (52% for essential drugs, 79% for oncology drugs) are more 
involved. Causes for drug shortages are underreported, as the cause is not known 
in 66% of the cases (n= 671). Production problems are reported in 27% of the cases 
(n= 671). Results are subjected to the different scopes of the considered reporting 
systems. cOnclusiOns: Reporting of drug shortages in Europe needs to be stand-
ardized and more transparency about the reasons for drug shortages is required to 
understand the problem. A link between production problems and market attrac-
tiveness and market capacity is recognized to be at the root of drug shortages in 
U.S. Such insights are highly lacking in Europe. Monitoring of the effect of national 
and European health policies on the sustainability of the drug market is required 
to present fundamental solutions for the problem of drug shortages in Europe.
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Objectives: Ponatinib was temporarily withdrawn by the FDA in October 2013 fol-
lowing safety concerns arising from its Phase III trial. This drug had previously been 
approved under the accelerated approval pathway. Three other oncologics have been 
withdrawn under similar conditions, further adding to concerns with this pathway. 
This research aims to provide an up-to-date systematic analysis of all oncolog-
ics approved under this pathway and analyse the time delay in obtaining regular 
approval. MethOds: Publically available assessments of any oncologic approved 
under the FDA accelerated approval pathway were sourced and the dates of acceler-
ated approval and conversion to regular approval were extracted. Results: 41 onco-
logics across 50 indications have been assessed under the FDA accelerated approval 
pathway, all but two of which have been approved. Of the approved indications, 50% 
(24/48) have been converted to regular approval with an average delay of 53 months 
(range 13-151 months). 6% (3/48) have been withdrawn from the market due to lack 
of efficacy and/or safety concerns arising from Phase III data. 44% (21/48) have not 
been converted to regular approval despite being on the market for an average of 
45 months (range 4–109 months). In these cases the mandatory confirmatory trials 
have not been completed and to date the FDA has not withdrawn a single oncologic 
from the market for not conducting the confirmatory trial. cOnclusiOns: 21 onco-
logic indications approved under the accelerated approval process have not been 
converted to regular approval despite some being on the market for up to 9 years. 
Given that 11% (3/27) of the drugs that have conducted confirmatory trials have been 
withdrawn, completion of confirmatory data should become a strict, non-negotiable 
requirement with a defined time limit by which the data must be submitted. A fail-
ure to do so should see the FDA automatically withdrawing their license.
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Objectives: The European Medicines Agency (EMA) approved 19 oncologics across 
25 indications on the basis of pivotal Phase II data lacking an active comparator 
(Macaulay, ISPOR Dublin 2013). Approval was typically granted for indications in 
which there was no therapeutic alternative where a response rate of ≥ 35% was 
demonstrated. This research aims to define the circumstances under which the 
Food and Drug Administration (FDA) will approve oncologics on the basis of pivotal 
Phase II data and compare to those of the EMA. MethOds: A systematic search 
was undertaken for FDA oncologic submissions based on pivotal Phase II data and 
the acceptance decision, indication, and level of benefit were extracted. Results: 
31 oncologics across 38 indications were submitted to the FDA on the basis of piv-
otal Phase II data. All of which were non-comparative and 36 were approved. This 
included all drugs approved by the EMA on this basis except trabectidin. 32 indi-
cations were approved under the accelerated approval pathway, only 47% (15/32) 
of which have been converted to regular approvals. Two of these drugs have been 
subsequently withdrawn from the market as they failed to show benefit in confirma-
tory trials (gefitinib and gemtuzumab), neither of which were EMA-approved for 
these indications. 72% (23/32) were FDA designated orphan indications. 78% (25/32) 
indications were for lines of therapy or diseases that had no relevant therapeutic 
alternatives. The response rates of approved drugs ranged from 11%-86%, while 
13 indications were approved with response rates of < 35%, which included the 
2 withdrawn drugs. cOnclusiOns: Pivotal Phase II data can support FDA onco-
logic approvals for indications that lack therapeutic alternatives and demonstrate 
response rates of ≥ 10% (versus ≥ 35% for the EMA). The lower threshold enables more 
